DE602004028150D1 - Aminopyrazolderivate als gsk-3-inhibitoren - Google Patents

Aminopyrazolderivate als gsk-3-inhibitoren

Info

Publication number
DE602004028150D1
DE602004028150D1 DE602004028150T DE602004028150T DE602004028150D1 DE 602004028150 D1 DE602004028150 D1 DE 602004028150D1 DE 602004028150 T DE602004028150 T DE 602004028150T DE 602004028150 T DE602004028150 T DE 602004028150T DE 602004028150 D1 DE602004028150 D1 DE 602004028150D1
Authority
DE
Germany
Prior art keywords
gsk
inhibitors
prodrugs
stereoisomers
inter alia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004028150T
Other languages
English (en)
Inventor
John William Benbow
Daniel Wei-Shung Kung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602004028150D1 publication Critical patent/DE602004028150D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
DE602004028150T 2003-11-26 2004-11-15 Aminopyrazolderivate als gsk-3-inhibitoren Active DE602004028150D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52543603P 2003-11-26 2003-11-26
PCT/IB2004/003749 WO2005051919A1 (en) 2003-11-26 2004-11-15 Aminopyrazole derivatives as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
DE602004028150D1 true DE602004028150D1 (de) 2010-08-26

Family

ID=34632981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028150T Active DE602004028150D1 (de) 2003-11-26 2004-11-15 Aminopyrazolderivate als gsk-3-inhibitoren

Country Status (10)

Country Link
US (1) US7671072B2 (de)
EP (1) EP1689721B1 (de)
JP (1) JP4864719B2 (de)
AT (1) ATE473967T1 (de)
BR (1) BRPI0416989A (de)
CA (1) CA2547283C (de)
DE (1) DE602004028150D1 (de)
DK (1) DK1689721T3 (de)
ES (1) ES2347152T3 (de)
WO (1) WO2005051919A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938279B (zh) * 2004-01-30 2011-09-14 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白调控剂
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20090318430A1 (en) * 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR100832747B1 (ko) * 2006-10-27 2008-05-27 한국화학연구원 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2011066544A2 (en) * 2009-11-30 2011-06-03 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
WO2012006276A1 (en) * 2010-07-06 2012-01-12 North Carolina State University Inhibition of bacterial biofilms with aryl carbamates
US9125408B2 (en) 2010-09-01 2015-09-08 North Carolina State University Use of aryl carbamates in agriculture and other plant-related areas
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN109651171A (zh) * 2019-01-13 2019-04-19 苏州鹏旭医药科技有限公司 依拉戈利及其钠盐的中间体及其盐的制备方法和应用
CN113330000A (zh) 2019-01-31 2021-08-31 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
JP2022020583A (ja) * 2020-07-20 2022-02-01 ファイザー・インク 併用療法
WO2022135365A1 (en) * 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Disubstituted cyclopentane kinase inhibitors
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
WO2023274397A1 (zh) * 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法和用途
WO2023083201A1 (zh) * 2021-11-09 2023-05-19 上海拓界生物医药科技有限公司 一种氨基吡唑衍生物及其制备方法和用途
WO2023141852A1 (zh) * 2022-01-27 2023-08-03 益方生物科技(上海)股份有限公司 Cdk2抑制剂及其制备方法和用途
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2
WO2024035830A1 (en) * 2022-08-11 2024-02-15 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
WO2024066981A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 氘代吡唑类衍生物、药物组合物及应用与制备方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
DK169601B1 (da) * 1983-10-17 1994-12-19 Duphar Int Res Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE68916980T2 (de) * 1988-02-03 1994-11-17 Nippon Steel Corp Verfahren zum Herstellen kornorientierter Elektrostahlbleche mit hoher Flussdichte.
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
RU2099339C1 (ru) * 1990-02-06 1997-12-20 Пфайзер Инк. Производные пиперидина
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
RO110499B1 (ro) * 1991-05-31 1996-01-30 Pfizer Derivati de chinuclidina si compozitie farmaceutica continand acesti compusi
HU221634B1 (hu) * 1991-06-20 2002-12-28 Pfizer Inc. Nitrogéntartalmú heterociklusos vegyületek fluor-alkoxi-benzilamino-származékai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5530161A (en) * 1991-07-08 1996-06-25 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
EP0533268B1 (de) * 1991-09-18 2001-08-16 Glaxo Group Limited Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE295420T1 (de) * 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ATE147385T1 (de) * 1992-11-12 1997-01-15 Pfizer Chinuclidin derivat als substanz p antagonist
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
PT689536E (pt) 1993-03-16 2001-11-30 Pfizer Derivados de naftaleno
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
JP3351065B2 (ja) * 1993-10-29 2002-11-25 日本メクトロン株式会社 ２，２−ジフェニルヘキサフルオロプロパン類の製造法
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
NZ275151A (en) * 1994-01-31 1998-02-26 Pfizer 3r*4s*3-[4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4 ,7-diol; isomers and salts
DE69531154T2 (de) * 1994-08-18 2004-04-08 Pfizer Inc. Neuroprotektive 3-(piperidinyl-1)-chroman-4,7-diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)-alkanolderivate
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
CA2244897C (en) * 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
DE69712325T2 (de) * 1996-03-08 2002-11-28 Hoffmann La Roche Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
PL329170A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of benzi(idene)-lactam, their production and application as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors
DE69716916T2 (de) * 1996-07-13 2003-07-03 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ID19430A (id) * 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
JP3299975B2 (ja) * 1996-07-18 2002-07-08 ファイザー・インク マトリックスメタロプロテアーゼのホスフィン酸塩ベース阻害薬
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US5843504A (en) * 1996-10-15 1998-12-01 Townsend Engineering Company Method and apparatus for coagulating the outer surface of a sausage strand discharged from a sausage extruding machine
ATE272640T1 (de) * 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
IL131042A (en) * 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6294532B1 (en) * 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
DE59802413D1 (de) * 1997-09-24 2002-01-24 Infineon Technologies Ag o-Amino(thio)phenol-carbonsäuren und deren Herstellung
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6380203B1 (en) * 1998-01-14 2002-04-30 Merck & Co., Inc. Angiogenesis inhibitors
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) * 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EP1082305A4 (de) * 1998-05-29 2001-09-26 Sugen Inc Pyrrol substituierte 2-indolinone wirksam als proteinkinase-hemmer
EA200300205A1 (ru) * 2000-08-31 2003-06-26 Пфайзер Продактс Инк. Производные пиразола и их применение в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
WO2005051919A1 (en) 2005-06-09
CA2547283C (en) 2010-11-09
US20070276010A1 (en) 2007-11-29
JP4864719B2 (ja) 2012-02-01
CA2547283A1 (en) 2005-06-09
ATE473967T1 (de) 2010-07-15
BRPI0416989A (pt) 2007-02-06
DK1689721T3 (da) 2010-09-20
ES2347152T3 (es) 2010-10-26
JP2007512315A (ja) 2007-05-17
EP1689721B1 (de) 2010-07-14
EP1689721A1 (de) 2006-08-16
US7671072B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA200901373A1 (ru) Аминогетероциклические соединения
EA200401114A2 (ru) Замещённые гидроксиэтиламины
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EP1841426A4 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
DE60236322D1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
JO2282B1 (en) Oxazole derivatives
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
EP1817312A4 (de) Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
GB0318447D0 (en) Therapeutic agents
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
MXPA05010293A (es) 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EP2077719A4 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
DE602004008658D1 (de) Behandlung neurodegenerativer krankheiten
IL184439A0 (en) 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1